139 | ENHANCED CAR T‐CELL EXPANSION AND DURABLE COMPLETE RESPONSES WITH NKTR‐255 PLUS LISOCABTAGENE MARALEUCEL IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA
Alexandre V. Hirayama(University of Washington), Cameron J. Turtle(The University of Sydney), Erik L. Kimble(University of Washington), David G. Maloney(Fred Hutch Cancer Center), Natalie Wuliji(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Z. Lee(Nektar Therapeutics (United States)), Aiko Torkelson(Fred Hutch Cancer Center), Aude G. Chapuis(University of Washington), Brian G. Till(University of Washington), Melinda A. Biernacki(Fred Hutch Cancer Center), Rahul Banerjee(University of Washington), Mazyar Shadman(University of Washington), Delaney Kirchmeier(Fred Hutch Cancer Center), Filippo Milano(Fred Hutch Cancer Center), Lorenzo Iovino(University of Pisa), Mario Q. Marcondes(Nektar Therapeutics (United States)), Folashade Otegbeye(University Hospitals of Cleveland), Edus H. Warren(University of Washington), Ryan D. Cassaday(University of Washington), Lawrence Fong(UCSF Helen Diller Family Comprehensive Cancer Center), James H. Wright(Fred Hutch Cancer Center), Barbara Pender(Fred Hutch Cancer Center), Jordan Gauthier(Seattle Cancer Care Alliance), Kristina Braathen(Fred Hutch Cancer Center), Mohamed L. Sorror(University of Washington Medical Center)
Cited by 1
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
|Nature Medicine|1999|1.1k